Vaxcyte Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PCVX$67.53+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net Loss | $(402,266) | $(223,485) | $(100,077) |
| Other comprehensive loss: | |||
| Unrealized gains (losses) on investments | 538 | (120) | (241) |
| Foreign currency translation adjustments, net | 2 | — | — |
| Comprehensive Loss | $(401,726) | $(223,605) | $(100,318) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.